William Blair Comments on Diplomat Pharmacy Inc’s Q1 2018 Earnings (DPLO)
Diplomat Pharmacy Inc (NYSE:DPLO) – Equities research analysts at William Blair lifted their Q1 2018 earnings per share (EPS) estimates for Diplomat Pharmacy in a report released on Friday. William Blair analyst J. Kreger now forecasts that the company will earn $0.28 per share for the quarter, up from their prior forecast of $0.24. William Blair also issued estimates for Diplomat Pharmacy’s Q2 2018 earnings at $0.28 EPS, Q3 2018 earnings at $0.32 EPS, Q4 2018 earnings at $0.34 EPS, FY2018 earnings at $1.22 EPS, Q2 2019 earnings at $0.37 EPS and Q3 2019 earnings at $0.40 EPS.
Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.10. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.16 billion. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The company’s revenue for the quarter was down 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.21 earnings per share.
DPLO has been the topic of a number of other reports. BidaskClub raised Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 5th. Needham & Company LLC restated a “buy” rating and set a $23.75 price objective (up from $19.75) on shares of Diplomat Pharmacy in a research report on Wednesday, October 4th. Mizuho set a $16.00 price objective on Diplomat Pharmacy and gave the company a “hold” rating in a research report on Tuesday, October 24th. Zacks Investment Research upgraded Diplomat Pharmacy from a “hold” rating to a “strong-buy” rating and set a $24.00 price objective on the stock in a research report on Tuesday, October 10th. Finally, Leerink Swann boosted their price objective on Diplomat Pharmacy from $16.00 to $20.00 and gave the company a “market perform” rating in a research report on Tuesday, November 7th. Five analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Diplomat Pharmacy presently has a consensus rating of “Buy” and an average target price of $20.72.
Shares of Diplomat Pharmacy (NYSE DPLO) traded up $0.59 during midday trading on Monday, hitting $20.63. 525,400 shares of the company were exchanged, compared to its average volume of 798,866. Diplomat Pharmacy has a fifty-two week low of $12.25 and a fifty-two week high of $21.99. The company has a current ratio of 1.34, a quick ratio of 0.82 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $1,420.00, a PE ratio of 171.92, a P/E/G ratio of 3.71 and a beta of 0.61.
Several large investors have recently made changes to their positions in DPLO. PNC Financial Services Group Inc. lifted its position in shares of Diplomat Pharmacy by 46.7% during the second quarter. PNC Financial Services Group Inc. now owns 8,779 shares of the company’s stock worth $130,000 after acquiring an additional 2,794 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its stake in Diplomat Pharmacy by 4.9% in the second quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock valued at $152,000 after acquiring an additional 480 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in Diplomat Pharmacy by 11.9% in the second quarter. Janney Montgomery Scott LLC now owns 11,193 shares of the company’s stock valued at $166,000 after acquiring an additional 1,193 shares during the last quarter. Bank of Montreal Can increased its stake in Diplomat Pharmacy by 3.0% in the second quarter. Bank of Montreal Can now owns 11,600 shares of the company’s stock valued at $172,000 after acquiring an additional 340 shares during the last quarter. Finally, First Allied Advisory Services Inc. bought a new position in Diplomat Pharmacy in the second quarter valued at $183,000. 72.21% of the stock is currently owned by institutional investors.
In other Diplomat Pharmacy news, President Joel Saban purchased 10,000 shares of the firm’s stock in a transaction dated Monday, November 20th. The shares were bought at an average price of $15.24 per share, for a total transaction of $152,400.00. Following the purchase, the president now owns 12,000 shares in the company, valued at approximately $182,880. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Atul Kavthekar purchased 2,000 shares of the firm’s stock in a transaction dated Monday, November 20th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $30,000.00. Following the purchase, the chief financial officer now owns 2,000 shares in the company, valued at approximately $30,000. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 15,000 shares of company stock valued at $228,780. 30.20% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This piece was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://theolympiareport.com/2017/12/26/william-blair-comments-on-diplomat-pharmacy-incs-q1-2018-earnings-dplo-3.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with Analyst Ratings Network's FREE daily email newsletter.